Certuity LLC Lowers Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Certuity LLC cut its stake in shares of Zoetis Inc. (NYSE:ZTS) by 88.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,386 shares of the company’s stock after selling 11,131 shares during the period. Certuity LLC’s holdings in Zoetis were worth $226,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Cherry Creek Investment Advisors Inc. raised its stake in shares of Zoetis by 2.0% during the third quarter. Cherry Creek Investment Advisors Inc. now owns 3,021 shares of the company’s stock worth $590,000 after purchasing an additional 58 shares during the last quarter. Hancock Whitney Corp increased its stake in Zoetis by 0.3% in the 3rd quarter. Hancock Whitney Corp now owns 18,569 shares of the company’s stock valued at $3,628,000 after buying an additional 61 shares during the period. Strategy Asset Managers LLC raised its position in Zoetis by 3.5% during the 3rd quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company’s stock worth $356,000 after buying an additional 62 shares during the last quarter. Procyon Advisors LLC lifted its stake in shares of Zoetis by 1.4% in the 4th quarter. Procyon Advisors LLC now owns 4,712 shares of the company’s stock worth $768,000 after acquiring an additional 63 shares during the period. Finally, Aberdeen Wealth Management LLC boosted its holdings in shares of Zoetis by 1.9% in the third quarter. Aberdeen Wealth Management LLC now owns 3,566 shares of the company’s stock valued at $697,000 after acquiring an additional 68 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Trading Down 4.9 %

Shares of ZTS stock opened at $165.28 on Friday. The stock has a market cap of $74.57 billion, a P/E ratio of 31.07, a P/E/G ratio of 2.77 and a beta of 0.90. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.53. The business has a fifty day simple moving average of $169.08 and a 200-day simple moving average of $179.08.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. On average, analysts forecast that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.21%. Zoetis’s dividend payout ratio is currently 37.59%.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Stifel Nicolaus cut their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. UBS Group initiated coverage on Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price target for the company. Piper Sandler dropped their price objective on Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a report on Monday. Finally, Leerink Partners initiated coverage on Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price objective for the company. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Zoetis has an average rating of “Buy” and a consensus price target of $214.00.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.16% of the stock is owned by corporate insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.